Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population

Five -tyrosine kinase inhibitors ( TKIs) are currently available in the first-line setting for non-small-cell lung cancer (NSCLC) in Japan. The aim here was to compare the relative efficacy of TKIs in the Japanese population. A systematic review identified randomized controlled trials examining the efficacy of first-line TKIs. A Bayesian network meta-analysis was used to assess these TKI comparisons for progression-free survival (PFS). A total of seven randomized controlled trials were identified and considered for network meta-analysis. Dacomitinib showed a trend toward improved PFS versus all comparators. Dacomitinib demonstrated a trend toward improved PFS and therefore, should be considered one of the standard first-line therapies for Japanese patients diagnosed with EGFR+ non-small-cell lung cancer.